Skip to content

Reported May 8, 2025 · Before market open

Next report

Aug 6, 2026 (in a month)
EPS estimate-$0.30

Financials

Q1 2025

Income statement

See full
Revenue$7.1M+33.5%
Gross profit$6.4M+35.8%
Operating income-$15.2M+22.0%
Net income$73.0M+499%
EPS (diluted)$1.83+369%

Balance sheet

See full
Cash & equivalents$227.6M+323%
Total equity$221.7M+145%
Total assets$234.0M+111%

Cash flow

See full
Operating cash flow-$11.9M+39.6%
CapEx$551.0K-25.4%
Free cash flow-$12.4M+39.1%

Valuation & ratios

Profitability

See full
Gross margin88.7%+1.0pp
Operating margin-227.4%-48.8pp
Net margin99.4%+57.0pp
FCF margin-191.6%-39.0pp

Returns & leverage

See full
Return on equity17.7%+10.0pp
Current ratio19×+13.8×

Segments

By segment

See full
Reportable$7.1M+33.5%

Versus estimates

Ask the moment Whitehawk Therapeutics, Inc. Common Stock reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Whitehawk Therapeutics, Inc. Common Stock report Q1 2025 earnings?
Whitehawk Therapeutics, Inc. Common Stock (WHWK) reported Q1 2025 earnings on May 8, 2025 before market open.
What were Whitehawk Therapeutics, Inc. Common Stock's Q1 2025 revenue and EPS?
Whitehawk Therapeutics, Inc. Common Stock reported revenue of $7.1M and diluted EPS of $-0.36 for Q1 2025.
Did Whitehawk Therapeutics, Inc. Common Stock beat estimates in Q1 2025?
EPS beat the consensus estimate of $-0.46 by $0.10.
Where can I find Whitehawk Therapeutics, Inc. Common Stock's Q1 2025 SEC filings?
You can read the 10-Q periodic report (0001628280-25-023932) directly on SEC EDGAR. The filing index links above go to sec.gov.